Talking Life Sciences

Episode 18 - Regulatory and Policy Developments from South Africa – SAHPRA’s Proposed Black Economic Empowerment (BEE) Policy

13 min · 24 okt 2024
aflevering Episode 18 - Regulatory and Policy Developments from South Africa – SAHPRA’s Proposed Black Economic Empowerment (BEE) Policy artwork

Beschrijving

In this episode of Covington’s Life Sciences Podcast [https://www.cov.com/en/topics/talking-life-sciences-audiocast], Mosa Mkhize [https://www.cov.com/en/professionals/m/mosa-mkhize] and Deon Govender [https://www.cov.com/en/professionals/g/deon-govender] discuss Regulatory and policy developments from South Africa: SAHPRA’s proposed Black Economic Empowerment (BEE) policy and its potential impact on license holders for medicines and medical devices

Reacties

0

Wees de eerste die een reactie plaatst

Meld je nu aan en word lid van de Talking Life Sciences community!

Begin hier

2 maanden voor € 1

Daarna € 9,99 / maand · Elk moment opzegbaar.

  • Podcasts die je alleen op Podimo hoort
  • 20 uur luisterboeken / maand
  • Gratis podcasts

Alle afleveringen

18 afleveringen

aflevering Episode 14 - EU Pharma Law Review – Focus on Incentives artwork

Episode 14 - EU Pharma Law Review – Focus on Incentives

In this episode of Covington’s Life Sciences Podcast [https://www.cov.com/en/topics/talking-life-sciences-audiocast], Marie Doyle-Rossi [https://www.cov.com/en/professionals/d/marie-doyle-rossi], Anna Wawrzyniak [https://www.cov.com/en/professionals/w/anna-wawrzyniak], and Valeria Sturla [https://www.cov.com/en/professionals/s/valeria-sturla] discuss the position adopted by the European Parliament on 10 April 2024 on the Commission proposal to reform the core EU pharmaceutical legislation. Parliament’s position comes less than a year since the Commission published its proposal, and constitutes a significant step in the legislative process. Although many of the Parliament’s amendments to the Commission proposal can be seen as improvements by the innovative industry, many challenges and some unresolved questions remain, especially in relation to the incentive regime. During this audiocast, we therefore discuss improvements, challenges and unresolved questions of the EU Pharma law review, with a particular focus on incentives.

10 mei 202414 min